in the regulation of fibrinolysis through the 10 IU/ml) and hirudin (20 and 100 TIU/ml). Samples synthesis and secretion of plasminogen actiwere obtained before and 2, 6, and 24 hours after vators (tissue plasminogen activator [t-PA] and urostimulation. mRNA analysis was conducted by rekinase plasminogen activator [u-PA]) and plasminoverse transcription followed by polymerase chain gen activator inhibitor-1 (PAI-1) [1]. Several studies reaction, and PAI-1 antigen was determined by suggest that PAI-1, the main plasminogen activator ELISA. Addition of UFH (10 IU/ml) to HUVEC inhibitor found in plasma, plays an important pathoresulted in a decrease of PAI-1 mRNA at 6 hours physiological role. Raised plasma levels have been (40% reduction) and 24 hours (60% reduction) and associated with thrombosis [2-4], while defective PAI-1 antigen. Hirudin, however, did not modify PAI-1 is associated with a bleeding tendency [5]. significantly the PAI-1 mRNA nor the inhibitor se-PAI-1 is a 50-kD glycoprotein containing 379 cretion. The addition of UFH (10 or 100 IU/ml) aminoacids and 3 N-glycosylation sites, which exto endotoxin-stimulated HUVEC also reduced the ists in different conformations in vivo. Endothelial increased PAI-1 mRNA and antigen secretion cells synthesize an active form that spontaneously (45%), whereas no effect could be observed with converts to the latent or inactive form due to conhirudin. Our results suggest that UFH, but not formational changes of protein tertiary structure hirudin, by reducing the endothelial expression of [6,7]. The PAI-1 gene is located in chromosome 7, and it has 12.2 kb organized in nine exons separated by eight introns [8,9]. The 3Ј untranslated region